Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Duke University Medical Center, Durham, NC, United States



Survival: 5.9 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Durham, NC
   
Hospital: Duke University Medical Center
   
Journal: Link
   
Date: 3/2009

Description:
Patients:
This phase 2 trial involved 66 patients, 44 of whom were male. Of these, 34 patients had glioblastoma multiforme, 28 had anaplastic astrocytoma, and 4 had anaplastic oligodendroglioma. Tumors in all patients were resistant to temozolomide. The median age of these patients was 51, with a range of 21-69.

Treatment:
Patients were given a chemotherapeutic drug, temozolomide, which blocks DNA replication and growth of cancer cells. In addition, a biologic agent called O6-benzylguanine was administered. This drug blocks a DNA repair protein in cells that might be involved in temozolomide resistance.

Toxicity:
Grade 4 toxicities, most commonly neutropenia, but also thrombocytopenia, were observed in 48% of patients. One patient died of gastrointestinal perforation, which is reported to be likely due to a pre-existing condition.

Results:
The median overall survival for all patients in this study was 5.9 months, 4.6 months for patients with GBM, and 7.8 months for patients with anaplastic glioma. The progression-free survival rate at 6 months was 17% overall, 9% for those with GBM, and 25% for anaplastic glioma.

Correspondence: Dr. Henry Friedman; e-mail: fried003@mc.duke.edu

E-mail to a Friend Email Physician More Information